DK1012244T3 - Rhabdovira med genteknologisk manipulerede kapper - Google Patents

Rhabdovira med genteknologisk manipulerede kapper

Info

Publication number
DK1012244T3
DK1012244T3 DK98933339T DK98933339T DK1012244T3 DK 1012244 T3 DK1012244 T3 DK 1012244T3 DK 98933339 T DK98933339 T DK 98933339T DK 98933339 T DK98933339 T DK 98933339T DK 1012244 T3 DK1012244 T3 DK 1012244T3
Authority
DK
Denmark
Prior art keywords
hiv
recombinant
virus
receptor
gene
Prior art date
Application number
DK98933339T
Other languages
English (en)
Inventor
John K Rose
Mathias Schell
Erik E Johnson
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Application granted granted Critical
Publication of DK1012244T3 publication Critical patent/DK1012244T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Confectionery (AREA)
DK98933339T 1997-07-11 1998-07-10 Rhabdovira med genteknologisk manipulerede kapper DK1012244T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5236697P 1997-07-11 1997-07-11
PCT/US1998/014527 WO1999002657A1 (en) 1997-07-11 1998-07-10 Rhabdoviruses with reengineered coats

Publications (1)

Publication Number Publication Date
DK1012244T3 true DK1012244T3 (da) 2007-09-10

Family

ID=21977148

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98933339T DK1012244T3 (da) 1997-07-11 1998-07-10 Rhabdovira med genteknologisk manipulerede kapper

Country Status (10)

Country Link
EP (1) EP1012244B1 (da)
JP (1) JP4434478B2 (da)
AT (1) ATE361973T1 (da)
AU (1) AU731663B2 (da)
CA (1) CA2295858C (da)
DE (1) DE69837764T2 (da)
DK (1) DK1012244T3 (da)
ES (1) ES2287977T3 (da)
PT (1) PT1012244E (da)
WO (1) WO1999002657A1 (da)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
JP4413999B2 (ja) 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7314631B1 (en) 1997-05-23 2008-01-01 The United States Of America As Represented By The Department Of Health And Human Services Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7250171B1 (en) 1997-05-23 2007-07-31 United States Of America As Represented By The Dept. Of Health & Human Services Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
US7208161B1 (en) 1997-05-23 2007-04-24 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Production of attenuated parainfluenza virus vaccines from cloned nucleotide sequences
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
ES2301241T3 (es) 1998-06-12 2008-06-16 Mount Sinai School Of Medicine Of The City University Of New York Virus de influenza a atenuados, y composiciones inmunogenicas y formulaciones de vacunas que los contienen.
JP4531255B2 (ja) 1998-06-12 2010-08-25 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー ワクチンおよび医薬として使用される、改変されたインターフェロン拮抗活性を有する弱毒（−）鎖ウイルス
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
WO2001004335A2 (en) 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Human-bovine chimeric respiratory syncytial virus vaccines
ES2320239T3 (es) * 1999-09-17 2009-05-20 Wellstat Biologics Corporation Virus oncolitico.
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
EP1130089A1 (en) * 2000-02-17 2001-09-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Composition comprising membrane virus subviral target and fusion particles and vaccine comprising said composition
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
US6635416B2 (en) 2000-04-10 2003-10-21 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US8927206B2 (en) 2001-01-19 2015-01-06 Vironovative B.V. Virus causing respiratory tract illness in susceptible mammals
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
MXPA04008088A (es) 2002-02-21 2005-09-30 Medimmune Vaccines Inc Sistema de expresion del virus de parainfluenza recombinante y vacunas que comprenden antigenos heterologos derivados del metapneumovirus.
WO2003091401A2 (en) 2002-04-26 2003-11-06 Medimmune Vaccines, Inc. Multi plasmid system for the production of influenza virus
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
EP2494986A1 (en) 2003-04-25 2012-09-05 MedImmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
EP2581093B1 (en) 2003-06-16 2015-03-18 MedImmune, LLC Influenza hemagglutinin and neuraminidase variants
DE602004027537D1 (da) 2003-12-23 2010-07-15 Medimmune Inc
AU2005248377B2 (en) 2004-05-25 2011-03-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
EP2497492B1 (en) 2004-06-01 2018-08-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
EP1855713B1 (en) 2005-02-15 2016-04-27 Mount Sinai School of Medicine Genetically engineered equine influenza virus and uses thereof
ES2527503T3 (es) 2005-03-08 2015-01-26 Medimmune, Llc Virus influenza reordenantes
US7790434B2 (en) 2005-06-21 2010-09-07 Medimmune, Llc Methods and compositions for expressing negative-sense viral RNA in canine cells
CA2613283A1 (en) 2005-06-21 2007-01-04 Medimmune Vaccines, Inc. Methods and compositions for expressing a heterologous protease
MY147379A (en) 2005-12-02 2012-11-30 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
MX2008013388A (es) 2006-04-19 2009-03-02 Medimmune Llc Metodos y composiciones para expresar arn viral en sentido negativo en celulas caninas.
US7601356B2 (en) 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
WO2008021959A2 (en) 2006-08-09 2008-02-21 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
EP2069484B1 (en) 2007-06-18 2014-08-13 MedImmune, LLC Influenza B viruses having alterations in the hemaglutinin polypeptide
MX2011000437A (es) 2008-07-11 2012-03-07 Medimmune Llc Variantes de hemaglutinina y neuramnidasa de influenza.
US8591881B2 (en) 2009-02-05 2013-11-26 Mount Sinai School Of Medicine Chimeric Newcastle disease viruses and uses thereof
CN102361649A (zh) 2009-02-12 2012-02-22 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
EP2413962A1 (en) 2009-03-30 2012-02-08 Mount Sinai School of Medicine Influenza virus vaccines and uses thereof
DE102009024721A1 (de) 2009-06-12 2010-12-16 Erwin Bienek Dezentrale Ladestation für batteriebetriebene Elektromobile
WO2011014504A1 (en) 2009-07-27 2011-02-03 Mount Sinai School Of Medicine Of New York University Recombinant influenza virus vectors and uses thereof
US8828406B2 (en) 2009-07-30 2014-09-09 Icahn School Of Medicine At Mount Sinai Influenza viruses and uses thereof
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
CN104185476A (zh) 2011-09-20 2014-12-03 西奈山医学院 流感病毒疫苗及其应用
CN108641002A (zh) 2012-12-18 2018-10-12 西奈山伊坎医学院 流感病毒疫苗及其用途
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
SG10201802982WA (en) 2013-03-14 2018-06-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
JP6857498B2 (ja) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法
WO2016118937A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
AU2016222962B2 (en) 2015-02-26 2020-05-21 Boehringer Ingelheim Vetmedica Gmbh Bivalent swine influenza virus vaccine
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
WO2017031404A1 (en) 2015-08-20 2017-02-23 University Of Rochester Live-attenuated vaccine having mutations in viral polymerase for the treatment and prevention of canine influenza virus
WO2017031408A1 (en) 2015-08-20 2017-02-23 University Of Rochester Single-cycle virus for the development of canine influenza vaccines
JP2019520338A (ja) 2016-06-03 2019-07-18 ユニバーシティ オブ ロチェスター ウマインフルエンザウイルス弱毒生ワクチン
CN109641041A (zh) 2016-06-15 2019-04-16 西奈山伊坎医学院 流感病毒血细胞凝集素蛋白及其用途
CA3058652A1 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11576963B2 (en) 2018-02-27 2023-02-14 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (EIV) in horses
US11166996B2 (en) 2018-12-12 2021-11-09 Flagship Pioneering Innovations V, Inc. Anellovirus compositions and methods of use
CA3130781A1 (en) 2019-02-27 2020-09-03 University Of Rochester Multivalent live-attenuated influenza vaccine for prevention and control of equine influenza virus (eiv) in horses
RU2768032C1 (ru) * 2021-09-02 2022-03-23 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Генетическая конструкция для экспрессии генов mNG_CD4-CXCR4, рекомбинантная плазмида rVSV_mNG_CD4-CXCR4 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CXCR4, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp 41 ВИЧ-1 тропности X4
RU2769125C1 (ru) * 2021-09-02 2022-03-28 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Генетическая конструкция для экспрессии генов mNG_CD4-CCR5, рекомбинантная плазмида rVSV_mNG_CD4-CCR5 и рекомбинантный штамм вируса везикулярного стоматита rVSV_mNG_CD4-CCR5, обеспечивающий таргетный виролизис клеток, экспонирующих на своей поверхности белки gp120/gp41 ВИЧ-1 тропности R5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT702085E (pt) * 1994-07-18 2004-04-30 Karl Klaus Conzelmann Virus de arn de cadeia negativa nao segmentada infeccioso recombinante

Also Published As

Publication number Publication date
CA2295858A1 (en) 1999-01-21
EP1012244B1 (en) 2007-05-09
JP4434478B2 (ja) 2010-03-17
PT1012244E (pt) 2007-08-21
WO1999002657A1 (en) 1999-01-21
JP2003527064A (ja) 2003-09-16
EP1012244A4 (en) 2004-09-15
DE69837764T2 (de) 2008-01-31
DE69837764D1 (de) 2007-06-21
AU731663B2 (en) 2001-04-05
CA2295858C (en) 2011-05-10
EP1012244A1 (en) 2000-06-28
AU8300298A (en) 1999-02-08
ATE361973T1 (de) 2007-06-15
ES2287977T3 (es) 2007-12-16

Similar Documents

Publication Publication Date Title
DK1012244T3 (da) Rhabdovira med genteknologisk manipulerede kapper
Kleny et al. Improved antigenicity of the HIV env protein by cleavage site removal
JP2003527064A5 (da)
Watanabe et al. Functional importance of the coiled-coil of the Ebola virus glycoprotein
DE3853422T2 (de) HIV-3-Retrovirus und seine Verwendung.
PT83434B (pt) Processo de preparacao de virus recombinantes, de peptidos ou proteinas e de vacinas contra o sindroma de imunodeficiencia adquirida
ES2099066T3 (es) Antigenos a partir de adn sintetico derivado del virus de la inmunodeficiencia humana (hiv-1).
AR248045A1 (es) Procedimiento para producir un virus de avipox recombinante, un cultivo de celulas eucariotica, una vacuna y para expresar la totalidad o parte de una proteina heterologa, secuencia de transferencia
Sergel et al. Mutations in the cytoplasmic domain of the fusion glycoprotein of Newcastle disease virus depress syncytia formation
KUWANO et al. Antiviral effect of TNF-α and IFN-γ secreted from a CD8+ influenza virus-specific CTL clone
DK641787A (da) Virusvektor, der koder for et glycoprotein fra det virus, der er ansvarligt for aids, vaccine, der omfatter virusvektoren eller glycoproteinet, samt antistof mod glycoproteinet
NO964874L (no) Fusjonsglykoprotein fra HCMV og HSV
Long et al. Functional role of the cytoplasmic tail domain of the major envelope fusion protein of group II baculoviruses
AP9901615A0 (en) Multiple branch peptide constructions.
DK76688D0 (da) Vaccine indeholdende f-proteinet fra aids-virus
ATE122055T1 (de) Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
Carvalho et al. Marituba (Bunyaviridae) virus replication in cultured Aedes albopictus cells and in L-A9 cells
WO1999014378A3 (en) Methods using interleukin 4 to treat hiv infection
DE69938044D1 (de) Neue post-transkriptionelle regulationselemente und deren verwendung
AU8188187A (en) Viral vector and recombinant DNA coding, in particular, for the p25 protein of the virus that is a causal agent of aids, infected cell culture, protein obtained, vaccine and antibodies obtained
JPWO2019213305A5 (da)
OH Immunology of viral infections
CA2339850A1 (en) A non-cytolytic recombinant hiv-1 vaccine
Czarniecki et al. Disparate response of encephalomyocarditis virus and MM virus to interferon in JLS-V9R cells
TH22767A (th) เพทไทด์ชนิดหลายแขนงที่สร้างขึ้นสำหรับใช้ต่อ hiv